Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial

Abstract

IntroductionNeoadjuvant chemotherapy for breast cancer treatment is prescribed to facilitate surgery and provide confirmation of drug-sensitive disease, and the achievement of pathological complete response (pCR) predicts improved long-term outcomes. Docosahexaenoic acid (DHA) has been shown to reduce tumour growth in preclinical models when combined with chemotherapy and is known to beneficially modulate systemic immune function. The purpose of this trial is to investigate the benefit of DHA supplementation in combination with neoadjuvant chemotherapy in patients with breast cancer.Methods and analysisThis is a double-blind, phase II, randomised controlled trial of 52 women prescribed neoadjuvant chemotherapy to test if DHA supplementation enhances chemotherapy efficacy. The DHA supplementation group will take 4.4 g/day DHA orally, and the placebo group will take an equal fat supplement of vegetable oil. The primary outcome will be change in Ki67 labelling index from prechemotherapy core needle biopsy to definitive surgical specimen. The secondary endpoints include assessment of (1) DHA plasma phospholipid content; (2) systemic immune cell types, plasma cytokines and inflammatory markers; (3) tumour markers for apoptosis and tumour infiltrating lymphocytes; (4) rate of pCR in breast and in axillary nodes; (5) frequency of grade 3 and 4 chemotherapy-associated toxicities; and (6) patient-perceived quality of life. The trial has 81% power to detect a significant between-group difference in Ki67 index with a two-sided t-test of less than 0.0497, and accounts for 10% dropout rate.Ethics and disseminationThis study has full approval from the Health Research Ethics Board of Alberta - Cancer Committee (Protocol #: HREBA.CC-18-0381). We expect to present the findings of this study to the scientific community in peer-reviewed journals and at conferences. The results of this study will provide evidence for supplementing with DHA during neoadjuvant chemotherapy treatment for breast cancer.Trial registration numberNCT03831178

The Novel Antitumor Compound HCA Promotes Glioma Cell Death by Inducing Endoplasmic Reticulum Stress and Autophagy

“…Due to these anti-cancer properties, clinical trials have been developed to assess the potential of using fish oil or n-3 PUFAs to prevent and treat cancer [ 13 ]. In fact, there are clinical trials investigating the benefit of DHA supplementation (4.4 g/day of DHA, orally) in combination with neoadjuvant chemotherapy in breast cancer patients [ 14 ], but its benefits as an antitumor drug are still unclear. As such, HCA may potentially be suitable to treat neurodegenerative diseases in the CNS and/or cancer, due to its activity as an omega-3 PUFA, but with a different metabolization pathway, compared to DHA [ 8 , 15 , 16 , 17 ].…”

BLBP Is Both a Marker for Poor Prognosis and a Potential Therapeutic Target in Paediatric Ependymoma

“…Importantly, this may support the recent benefits associated to a ketogenic diet; however, the application of PPAR antagonists or DHA may prove more palatable. In support of this approach, a phase II clinical trial has recently been published proposing DHA supplementation alongside chemotherapy in breast cancer [ 35 ]. A similar approach could easily be applied in patients with brain tumours.…”

Critical Review on Fatty Acid-Based Food and Nutraceuticals as Supporting Therapy in Cancer

“…It must be evidenced that the use of a high-DHA containing source allowed for a clear differentiation of the DHA biological effects from the EPA+DHA sources [ 83 ]. The main molecular mechanisms involved in such activity were also addressed for DHA [ 84 , 85 , 86 ], and also in several DHA-anticancer couples, such as with sorafenib and paclitaxel [ 87 , 88 ], as well as by comparing effects of antitumoral with and without DHA [ 89 ]. It is necessary to recall at this point the previously discussed omega-3 contents in supplements, therefore in cancer the high DHA content becomes the most important requirement to ask of the formulation, coupled with the proof of the biodistribution to the membrane active site.…”